XTNT (Xtant Medical Holdings) Research & Development: $2.1 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTNT Xtant Medical Holdings Inc XTNT
27 GF Score
Price $0.44
GF Value $0.61
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Xtant Medical Holdings Research & Development?

Xtant Medical Holdings XTNT -0.82% 27 Research & Development is $2.1 Mil as of Mar. 2026. GuruFocus rates XTNT with a GF Score™ of 27/100 and a GF Value™ of $0.61 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Xtant Medical Holdings's Research & Development for the three months ended in Mar. 2026 was $0.4 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $2.1 Mil.

Xtant Medical Holdings  (AMEX:XTNT) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Xtant Medical Holdings Research & Development Related Terms

Xtant Medical Holdings Research & Development Historical Data

* Premium members only.

The historical data trend for Xtant Medical Holdings's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xtant Medical Holdings Research & Development Chart

Xtant Medical Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.87 0.92 1.34 2.39 2.10

Xtant Medical Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.44 0.57 0.63 0.46 0.44
XTNT
27GF Score
Xtant Medical Holdings Inc XTNT
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xtant Medical Holdings Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $2.1 Mil mean?
Xtant Medical Holdings (XTNT) has a Research & Development of $2.1 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Xtant Medical Holdings and its competitors.
Is Xtant Medical Holdings' Research & Development too high?
Xtant Medical Holdings' current Research & Development is $2.1 Mil. Overall, Xtant Medical Holdings has a GF Score™ of 27/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Xtant Medical Holdings' Research & Development compare to NNOX and POSC?
Xtant Medical Holdings' Research & Development of $2.1 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Xtant Medical Holdings and its competitors. Xtant Medical Holdings's current Research & Development is $2.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xtant Medical Holdings stock overvalued right now?
Based on GuruFocus' analysis, Xtant Medical Holdings (XTNT) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.61, compared to a current price of $0.44 — trading 27.8% below its estimated fair value. The current Research & Development is $2.1 Mil. Xtant Medical Holdings' overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Xtant Medical Holdings (XTNT), the current Research & Development is $2.1 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xtant Medical Holdings (XTNT) Overvalued in 2026?

Based on GuruFocus' analysis, Xtant Medical Holdings stock appears to be undervalued. The current stock price of $0.44 is trading 27.8% below its estimated GF Value™ of $0.61. GuruFocus considers Xtant Medical Holdings to be Modestly Undervalued.

Key valuation signals for XTNT:

  • Research & Development: $2.1 Mil
  • GF Value™: $0.61 vs. price of $0.44 (27.8% below fair value)
  • GF Score™: 27/100 with 4 warning signs

No single metric tells the full story. See the XTNT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Xtant Medical Holdings Business Description

Address 664 Cruiser Lane, Belgrade, MT, USA, 59714
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the U.S.
27GF Score

Get the complete analysis for XTNT

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.44
Price
$0.61
GF Value